Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05542576 · ClinicalTrials.gov registry record · Phase 1
Study of AMDX-2011P as a Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy
A Phase 1 study, sponsored by Amydis.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT05542576 is a Phase 1 study that has completed, run by Amydis. The registered enrollment target is 13 participants.
The verdict
NCT05542576, a Phase 1 study, has completed, sponsored by Amydis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this research study is to assess safety and tolerability of a single intravenous (given through a vein) dose of the investigational retinal tracer AMDX-2011P in patients with neurodegenerative diseases (Parkinson's disease and ALS).
Interventions
- DRUG AMDX2011P
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2022-08-24 |
| Est. Completion | 2023-03-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05542576
The ClinicalTrials.gov registry entry for NCT05542576 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amydis, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AMDX2011P is the first listed.
NCT05542576 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05542576 about?
NCT05542576 is a clinical study titled "Study of AMDX-2011P as a Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy". The purpose of this research study is to assess safety and tolerability of a single intravenous (given through a vein) dose of the investigational retinal tracer AMDX-2011P in patients with neurodegenerative diseases (Parkinson's disease and ALS).
What is the current status of trial NCT05542576?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2022-08-24. Estimated completion is 2023-03-15.
What interventions are being tested in trial NCT05542576?
The interventions under investigation include: AMDX2011P (DRUG).
Who is sponsoring clinical trial NCT05542576?
This trial is sponsored by Amydis, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.